Results 41 to 50 of about 939 (187)

Evaluation of the pharmacokinetic interaction and safety of ubrogepant coadministered with acetaminophen or nonsteroidal anti-inflammatory drugs: A randomized trial

Cephalalgia Reports, 2020
Background: Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist approved by the US Food and Drug Administration for acute treatment of migraine with or without aura in adults.
Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Kaifeng Lu, Kristi Womack, Danielle McGeeney, Antonia Periclou   +6 more
doaj   +1 more source

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review

Brain Sciences, 2022
Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies and non-peptide small molecules, also known as gepants.
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara   +1 more
doaj   +1 more source

A phase 1 study of the breast milk and plasma pharmacokinetics of zavegepant 10 mg intranasal dose in healthy lactating women. [PDF]

Headache
Abstract Objective This study evaluated the pharmacokinetics of zavegepant in human breast milk and plasma following a single, 10 mg dose of zavegepant nasal spray. Background Zavegepant nasal spray is a member of the gepant class of medications; small molecule inhibitors of the calcitonin gene‐related peptide receptor.
Jakate A, Weng Y, Shkrodova A, Fisniku O, Ding D, Morton K, Maligalig B, Garnick P, Liu J, Shahin MH.   +9 more
europepmc   +2 more sources

Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system

, 2023
Migraine has a high prevalence in the population and accounts for 12% of primary headaches. Ubrogepant is used for the treatment of acute migraine, and although some clinical trials have demonstrated the safety of Ubrogepant, its long-term safety in a ...
Zhisen Shen (632372), Shanshan Gu (498196), Hang Chen (23866), Bing Cao (1458769), Yiming Shen (6941957), Yuna Zhang (604190)   +5 more
core   +1 more source

The effect of multiple doses of ubrogepant on the pharmacokinetics of an oral contraceptive in healthy women: Results of an open-label, single-center, two-period, fixed-sequence study

Cephalalgia Reports, 2020
Background: Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist for acute treatment of migraine. This study evaluated potential drug–drug interactions between ubrogepant and an oral contraceptive containing ethinyl estradiol ...
Chi-Chung Li, John Palcza, Jialin Xu, Bob Thornton, Wendy Ankrom, Abhijeet Jakate, Eugene E Marcantonio   +6 more
doaj   +1 more source

Efficacy of 5-HT1F agonist versus CGRP-antagonists for treatment of acute migraine: A systematic review and network meta-analysis

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: Two new classes of drugs approved by USFDA for the treatment of acute migraine are non-peptide Calcitonin Gene-Related Peptide (CGRP) receptor antagonists (rimegepant and ubrogepant) and 5-HT1F receptor agonist lasmiditan.
Sharanabasayyaswamy Basayya Hiremath, Srinivas Devendrappa Lokikere   +1 more
doaj   +1 more source

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine [PDF]

Journal of Managed Care & Specialty Pharmacy, 2020
DISCLOSURES: No funding supported the writing of this commentary. The authors have nothing to disclose.
Meg, Franklin, Eric, Druyts
openaire   +2 more sources

Correction to: Ubrogepant: First Approval [PDF]

Drugs, 2020
The article Ubrogepant: First Approval, written by Lesley J. Scott, was originally published published Online First without Open Access. After publication online Allergan Sales, LLC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Allergan Sales, LLC.
openaire   +2 more sources

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. [PDF]

, 2020
OBJECTIVE: To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. BACKGROUND: Ubrogepant is an oral, calcitonin gene-related receptor antagonist in development for the acute treatment of migraine.
Jessica Ailani, Ailani, Jessica, Lu, Kaifeng, Finnegan, Michelle, Michelle Finnegan, Sung Yun Yu, Butler, Matthew, Richard B. Lipton, Lipton, Richard B, Trugman, Joel M, Joel M. Trugman, Hutchinson, Susan, Knievel, Kerry, Matthew Butler, Susan Hutchinson, Severt, Lawrence, Yu, Sung Yun, Kaifeng Lu, Kerry Knievel, Lawrence Severt   +19 more
core   +1 more source

Non-interacting, Non-opioid, and Non-barbiturate Containing Acute Medication Combinations in Headache: A Pilot Combinatorics Approach Based on DrugBank Database

Frontiers in Neurology, 2021
Background: Polypharmacy in abortive medications is often inevitable for patients with refractory headaches.Objective: We seek to enumerate an exhaustive list of headaches abortive medications that are without drug-drug interactions.Methods: We updated a
Victor Kaytser, Pengfei Zhang
doaj   +1 more source